Black Diamond Therapeutics (BDTX) Cash & Equivalents (2018 - 2026)

Black Diamond Therapeutics (BDTX) has 9 years of Cash & Equivalents data on file, last reported at $30.1 million in Q1 2026.

• Quarterly Cash & Equivalents fell 69.45% year-over-year to $30.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.1 million (down 69.45% YoY) and the FY2025 annual result came in at $21.0 million, down 42.39% from the prior year.
• Cash & Equivalents rose to $30.1 million in Q1 2026, from $21.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $98.4 million in Q1 2025 to a low of $21.0 million in Q4 2025.
• A 5-year average of $42.5 million and a median of $36.4 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2025 — Cash & Equivalents soared 287.16% — and 2026, when it sank 69.45%.
• Tracing BDTX's Cash & Equivalents over 5 years: stood at $34.3 million in 2022, then surged by 63.84% to $56.2 million in 2023, then plunged by 35.19% to $36.4 million in 2024, then tumbled by 42.39% to $21.0 million in 2025, then surged by 43.26% to $30.1 million in 2026.
• The last three Cash & Equivalents figures came in at $30.1 million (Q1 2026), $21.0 million (Q4 2025), and $30.9 million (Q3 2025), per Business Quant data.